Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein.
Cis is an Src homology 2 domain-containing protein, which binds to the erythropoietin receptor and decreases erythropoietin-stimulated cell proliferation. We show that Cis associates with the second tyrosine residue of the intracellular domain of the erythropoietin receptor (Tyr401). Two forms of Cis with molecular masses of 32 and 37 kDa were detected, and we demonstrate that the 37-kDa protein resulted from post-translational modifications of the 32-kDa form. Anti-ubiquitin antibodies recognized the 37-kDa form of Cis and the proteasome inhibitors N-acetyl-leucyl-leucyl-norleucinal and lactacystin inhibited its degradation, showing that the 37-kDa form of Cis is a ubiquitinated protein, which seems to be rapidly degraded by the proteasome. In erythropoietin-stimulated UT-7 cells, the activation of the erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) was transient and returned to basal levels after 30-60 min of erythropoietin stimulation. In contrast, these proteins remained strongly phosphorylated, and STAT5 remained activated for at least 120 min in the presence of proteasome inhibitors. These experiments demonstrate that the proteasomes are involved in the down-regulation of the erythropoietin receptor activation signals. Because the proteasome inhibitors induced the accumulation of both the ubiquitinated form of Cis and the Cis-erythropoietin receptor complexes, our results suggest that the ubiquitinated form of Cis could be involved in the proteasome-mediated inactivation of the erythropoietin receptor.
Verdier
F
F
Institut Cochin de Génétique Moléculaire, INSERM U363, Université René Descartes, 27 rue du Faubourg Saint Jacques, F75014 Paris, France.
Chrétien
S
S
Muller
O
O
Varlet
P
P
Yoshimura
A
A
Gisselbrecht
S
S
Lacombe
C
C
Mayeux
P
P
D000111:Acetylcysteine / Q000031:analogs & derivatives / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism*; D007976:Leupeptins / Q000494:pharmacology; D008894:Milk Proteins; D009097:Multienzyme Complexes / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D011485:Protein Binding; D011499:Protein Processing, Post-Translational; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D050799:STAT5 Transcription Factor; D015398:Signal Transduction; D050826:Suppressor of Cytokine Signaling Proteins; D015534:Trans-Activators / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism; D014452:Ubiquitins / Q000378:metabolism*; D018909:src Homology Domains
D000111:Acetylcysteine; D003546:Cysteine Endopeptidases; D015853:Cysteine Proteinase Inhibitors; D004268:DNA-Binding Proteins; D017874:Immediate-Early Proteins; D007976:Leupeptins; D008894:Milk Proteins; D009097:Multienzyme Complexes; D046988:Proteasome Endopeptidase Complex; D017467:Receptors, Erythropoietin; D050799:STAT5 Transcription Factor; D050826:Suppressor of Cytokine Signaling Proteins; D015534:Trans-Activators; D014443:Tyrosine; D014452:Ubiquitins; C063261:acetylleucyl-leucyl-norleucinal; C067713:lactacystin